The Broad Institute has licensed out CRISPR/Cas9 intellectual property to Transposagen, a Kentucky biotech that commercializes gene editing technology to construct rodent models of disease.
Via this non-exclusive license agreement, Transposagen will incorporate CRISPR technology into its existing suite of gene editing tools meant for researchers to conduct drug discovery work.
The addition of CRISPR “provides an unprecedented ability for precision gene editing without fear of undesired off-target effects,” Transposagen CEO John Printen said in a statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Broad Institute has licensed CRISPR technology several times now, as Genome Web points out – to Horizon Discovery, GE Healthcare, and Sigma-Aldrich.
[Image courtesy of BigStock Photos]
